Spectrum Pharma Highlights Four Abstracts On SPI-2012 And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS)

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas, from December 8-12, 2015.

MORE ON THIS TOPIC